Dr. Steffen
Wagner appointed as new Chief Executive Officer and
Andreas Stickler as new Chief
Financial Officer
LONDON, Nov. 18, 2021 /CNW/ - ADVANZ PHARMA Corp. Limited
("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical
company with a strategic focus on complex medicines in Europe,
today announced several changes in senior leadership roles as it
enters the next phase of its growth journey.
Dr Steffen Wagner is to become
the new Chief Executive Officer of ADVANZ PHARMA, starting early
2022. He succeeds Graeme Duncan, who
will step down from his role and become a special advisor to the
Board. Andreas Stickler will join
from Merck Healthcare as the new Chief Financial Officer,
succeeding Adeel Ahmad.
Dr Steffen Wagner is currently a
member of the executive management team at STADA Arzneimittel AG
and has been responsible for the company's European Markets
division. Steffen is a medical doctor by training, has previously
held senior roles with Biogen and within the Novartis Group, and
worked as a consultant at McKinsey & Company and Bain &
Company. He brings extensive international pharma experience that
will be highly valuable in supporting ADVANZ PHARMA's continued
journey. His predecessor, Graeme
Duncan, has been with ADVANZ PHARMA since 2014 and has
played a significant role in building the Company to date. He will
continue working with the Board as a special advisor.
Andreas Stickler will join as the
Company's new Chief Financial Officer in January 2022. Most recently, he has been CFO of
Merck Healthcare, part of Merck KGaA, where he also served as
Global Head of M&A and Business Development, driving major
strategic acquisitions. He brings a wealth of global finance,
healthcare and M&A expertise to the team. His predecessor,
Adeel Ahmad, has been with the
Company since 2013 and has helped deliver major transformation
projects and built a sustainable business from which to grow.
These two key additions to the executive team of ADVANZ PHARMA
are accompanied by several other senior leadership changes. On
November 1, 2021, Susanna El-Armale joined as Chief Corporate
Development Officer, following her prior role as Chief Corporate
Development Officer of Theramex and succeeding former Chief
Corporate Development Officer Guy
Clark. Susanna brings broad experience spanning both M&A
and BD activities and will be a central driver of the Company's
active corporate development agenda. In January 2022, Chris
Britten will join Susanna
El-Armale's team as Senior Vice President for M&A,
following his role as Head, M&A for Neuraxpharm. On
October 11, Anke Niedernberg joined
as Senior Vice President and Head of the Transformation Office. She
brings a broad skillset to the leadership team, having spent time
in private equity, consulting and running major change and growth
projects for Sandoz for the last ten years.
These senior leadership changes build upon ADVANZ PHARMA's
successful 2021 and will help fuel the Company's next phase of
growth. In 2021, the Company delivered continued strong financial
performance, succeeded in acquiring additional strategic assets,
commenced the European launch of a generic version of Lanreotide
and bolstered its organic pipeline with further in-licensing deals.
ADVANZ PHARMA continues building towards achieving its corporate
vision of becoming the "partner of choice" for complex specialty
and hospital medicines in Europe.
About ADVANZ PHARMA
ADVANZ PHARMA is headquartered in
London and has commercial
affiliates in Europe, North America and Australia, and supply chain, regulatory and
administrative operations in India. Furthermore, ADVANZ PHARMA has an
established global network of commercial partners throughout the
rest of the world. With an agile and experienced team, including
direct sales, marketing, and medical capability across many of
Europe's major markets, ADVANZ
PHARMA supplies, innovates and enhances the critical medicines
patients depend on, ensuring continued patient access and improving
healthcare outcomes. ADVANZ PHARMA has a broad expertise in several
therapeutic areas with strengths in the critical care,
anti-infectives, endocrinology, cardiovascular and central nervous
system therapeutic areas, along with direct sales access in
Europe, making it an attractive
partner when commercialising complex medicines, especially in the
hospital channel. To find out more, please visit our website:
https://www.advanzpharma.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/advanz-pharma-makes-key-changes-to-senior-leadership-to-further-accelerate-next-phase-of-growth-301427684.html
SOURCE ADVANZ PHARMA Corp.